株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

市中細菌性肺炎:世界の治験レビュー

Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 320828
出版日 ページ情報 英文 96 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.55円で換算しております。
Back to Top
市中細菌性肺炎:世界の治験レビュー Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017
出版日: 2017年06月30日 ページ情報: 英文 96 Pages
概要

市中細菌性肺炎は、胸痛、咳、痰の産生、呼吸困難、寒気、悪寒、発熱、または低血圧症に関連する、肺実質の急性細菌感染として定義され、胸部X線画像では、新たな肺葉または多葉性浸潤の存在を伴います。市中細菌性肺炎を引き起こす、代表的な細菌性病原体は、肺炎球菌、インフルエンザ菌、モラクセラ・カタラーリスなどです。また、クラミジア・ニューモニエ、マイコプラズマ・ニューモニエ、レジオネラ・ニューモフィラなど、典型的な細菌性病原体も、市中細菌性肺炎を引き起こします。

当レポートでは、市中細菌性肺炎の治療薬に関する治験について調査分析し、治験数および被験者数、段階別・相別の状況、有望企業、開発中の治療薬の情報、治験プロファイルなどについて、体系的な情報を提供しています。

目次

イントロダクション

地域別の治験

  • 国別の治験動向
    • アジア太平洋地域の主要国
    • 欧州の主要国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国における治験:感染性疾患の治験に対する市中細菌性肺炎の割合

G7諸国における治験:相別

G7諸国における治験:段階別

E7諸国における治験:感染性疾患の治験に対する市中細菌性肺炎の割合

E7諸国における治験:相別

E7諸国における治験:段階別

相別の治験

段階別の治験

評価項目別の治験

未完了の治験

一定期間に採用された被験者

スポンサータイプ別の治験

有望なスポンサー

  • 市中細菌性肺炎の治療薬の治験に参加している主要企業

有望薬

治験プロファイル

  • 主要企業の治験概要
    • Actavis plc
    • Cempra, Inc.
    • Pfizer Inc.
    • Cempra Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Nabriva Therapeutics AG
    • Cubist Pharmaceuticals, Inc.
    • Boehringer Ingelheim Auslandsbeteiligungs GmbH
    • Bayer AG
    • Basilea Pharmaceutica AG
  • 主要大学・研究機関・病院の治験概要
    • 横浜労災病院
    • Nagasaki Evaluation Organization for Clinical Interventions(NEOCI)
    • 中日本呼吸器臨床研究機構(CJLSG)
    • Albany Medical Center

主な臨床プロファイル

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4323CTIDB

GlobalData's clinical trial report, "Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017" provides an overview of Community-Acquired Bacterial Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials 21
  • Clinical Trials by Phase in E7 Countries 23
  • Clinical Trials in E7 Countries by Trial Status 24
  • Clinical Trials by Phase 25
  • In Progress Trials by Phase 26
  • Clinical Trials by Trial Status 27
  • Clinical Trials by End Point Status 29
  • Subjects Recruited Over a Period of Time 30
  • Clinical Trials by Sponsor Type 31
  • Prominent Sponsors 32
  • Top Companies Participating in Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials 34
  • Prominent Drugs 36
  • Latest Clinical Trials News on Community-Acquired Bacterial Pneumonia 38
  • Jun 05, 2017: Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017 38
  • Jun 02, 2017: Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin 38
  • Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media 38
  • Apr 25, 2017: Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic Data 39
  • Apr 21, 2017: Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups 40
  • Apr 13, 2017: Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin 40
  • Apr 11, 2017: Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia 41
  • Clinical Trial Profile Snapshots 42

Appendix 94

  • Abbreviations 94
  • Definitions 94
  • Research Methodology 95
  • Secondary Research 95
  • About GlobalData 96
  • Contact Us 96
  • Source 96

List of Tables

List of Tables

  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
  • Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 18
  • Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 22
  • Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Phase, 2017* 25
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 26
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
  • Community-Acquired Bacterial Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 31
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

List of Figures

List of Figures

  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
  • Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17
  • Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 21
  • Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 25
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 26
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
  • Community-Acquired Bacterial Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 31
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36
  • GlobalData Methodology 95
Back to Top